Turk J Hematol: 22 (4)
Volume: 22 Issue: 4 - 2005
1. Imatinib mesylate and the management of chronic myeloid leukemia (CML)
Ebru Koca, İbrahim C. Haznedaroğlu
Pages 161 - 172 (2360 accesses)
2. Factor V A4070G (His1299Arg) mutation in Turkish pediatric patients with thrombosis
Pages 173 - 178 (2461 accesses)
Pediatrik trombozda protrombotik mutasyonların rolü araştırılmaktadır. Faktör V geninde, trombozda başlıca patolojik bir durum olan aktive protein C direncine neden olan mutasyonlar (FV G1691A ve FV A4070G) ile tromboza katkıda bulunan bazı protrombotik mutasyonlar belirlenmiştir. Bu çalışmanın amacı pediatrik yaş grubundaki bireylerde FV A4070G mutasyonunun rolünü ortaya koymaktır. Çalışmaya 111`i inme tanılı 314 pediatrik yaştaki trombozlu birey ile 127 sağlıklı kontrol dahil edilmiştir. FV A4070G mutasyonu diğer protrombotik mutasyonlarla ve bunlardan bağımsız olarak değerlendirilmiştir. Pediatrik inme grubunda FV A4070G mutasyonunun bir risk faktörü olmadığı belirlenmiştir (OR: 1.04, CI %95: 0.56-1.93, p= 0.884). FV A4070G mutasyonunun rolünü araştırmak için HR2 haplotipine ait diğer polimorfizmlerin de çalışılması gerekmektedir.
The role of the prothrombotic mutations in pediatric thrombosis are being investigated. Mutations in the factor V gene (FV G1691A and FV A4070G) leading to activated protein C resistance, the main pathological condition in thrombosis and prothrombotic mutations contributing to thrombosis have been identified. The aim of this study is to reveal the role of FV A4070G mutation in pediatric thrombosis. 314 patients with thrombosis at pediatric age including also 111 stroke patients and 127 healthy controls were included to the study. The FV A4070G mutation was evaluated independently and also the combined effects with other prothrombotic mutations were also investigated. In pediatric stroke group FV A4070G was found not to be a risk factor with an OR of 1.04 (CI 95%: 0.56-1.93, p= 0.884). Further studies are needed to study the role of FV A4070G with other risk factors belong to HR2 haplotype.
3. Body mass index, fibrinogen and factor VII activity in male smokers and non-smokers living in an Urban industrialized
Omolade Awodu, Olutayo Ifedayo Ajayi, Adekunle Ademola Famodu, Maureen Borgu
Pages 179 - 184 (2236 accesses)
Differences in haemostatic parameters have been reported among smokers and non-smokers. However the relationships of these parameters with other risk factors of cardiovascular diseases have not been fully determined in Nigerians. We therefore aimed at assessing the relationship between fibrinogen, factor VII (FVII), age, body mass indeks (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP) in smokers and non-smokers living in an Urban Nigerian city. We studied 104 male Nigerians grouped into non-smokers (n= 74) and smokers (n= 30). Fibrinogen was measured using the clot weight method of Ingram and FVII was assayed by the bioassay method. Mean fibrinogen and FVII were found to be higher in smokers than non-smokers. There was no relationship between FVII and age (r= -0.0458) in non-smokers and a weak association was found between FVII and age in smokers (r= 0.3191). Both SBP and DBP were significantly associated with BMI in smokers (r= 0.6332, p= 0.0002) for DBP and (r= 0.4869, p= 0.0064) for SBP. Fibrinogen was only associated with DBP in non-smokers (r= 0.3273, p= 0.0047). FVII and fibrinogen were found to be higher in smokers compared to non- smokers, the difference was not statistically significant (p= 0.1965). The strength of the association of BMI and fibrinogen with blood pressure is higher for DBP in Nigerians. Extensive population studies should be conducted on smokers and non-smokers to confirm these associations.
4. Effects of high-dose methylprednisolone therapy on lymphocyte subtypes in patients with acute immune thrombocytopenic purpura
Ahmet Faik Öner, Ali Bay, Mehmet Kuru, Abdurrahman Üner, Şükrü Arslan, İmdat Dilek
Pages 185 - 189 (3092 accesses)
5. Interleukin-10 and interferon-gamma cytokine gene polymorphisms may be risk factors for chronic myelogenous leukemia
Bilkay Baştürk, Elif Evke, Ahmet Tunalı, Sema Karakuş
Pages 191 - 196 (3131 accesses)
6. Posttransplant lymphoma in renal and heart allograft recipients: a single center experience
Ayşen Timurağaoğlu, Aynur Uğur Bilgin, Murat Tuncer, İlhan Gölbaşı, Dilek Çolak, Seray Dizlek, Gülten Karpuzoğlu
Pages 197 - 203 (2804 accesses)
7. Rapid progression of acquired amegakaryocytic thrombocytopenia to myelodysplastic syndrome: case report
Mehmet Ali Erkurt, Emin Kaya, Murat Baran, Ece Yitmen, Soner Şenel, İrfan Kuku, İsmet Aydoğdu
Pages 205 - 208 (2060 accesses)
8. High-dose steroid-related osteonecrosis in a four-year-old child with acute lymphoblastic leukemia
Ali Bay, Ahmet Faik Öner, Ömer Etlik, Murat Doğan
Pages 209 - 212 (2132 accesses)
Osteonekroz akut lenfoblastik löseminin nadir bir komplikasyonudur ve yüksek doz steroid tedavisinin risk faktörlerinden biridir. En yüksek osteonekroz insidansı tanı anında 9-18 yaşları arasında olan çocuklarda görülmektedir ve beş yaş altında nadirdir. Biz akut lenfoblastik lösemi nedeniyle iki kez remisyon indüksiyon kemoterapisi aldıktan sonra kemik ağrısı ve yürümede güçlük yakınması başlayan ve diz ekleminde osteonekroz ve fraktür gelişen dört yaşında bir olgu sunduk.
Osteonecrosis is an uncommon complication of acute lymphoblastic leukemia. One of the risk factor is high-dose corticosteroid therapy. The highest incidence of osteonecrosis is observed in children 9 to 18 years old at diagnosis and it is a rare condition below 5 years of age. We describe a 4 year-old child with acute lymphoblastic leukemia and complaints of progressive bone pain and walking difficulty who developed osteonecrosis and bone fracture after two remission induction chemotherapy.
T. Roshni Paul, Shantveer Uppin, Laxmi Srinivas
Page 213 (1724 accesses)